Price
Financials
Standalone, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 13.41 | 17.98 | 12.06 | 5.72 | 3.10 | 3.05 | 7.40 | 2.77 | 8.84 | 9.39 | 9.83 | 8.77 |
| Expenses | 10.38 | 13.90 | 9.65 | 4.39 | 2.38 | 2.60 | 6.59 | 2.74 | 6.49 | 5.33 | 6.50 | 5.47 |
| Operating Profit | 3.03 | 4.08 | 2.41 | 1.33 | 0.72 | 0.45 | 0.81 | 0.03 | 2.35 | 4.06 | 3.33 | 3.30 |
| OPM % | 22.60% | 22.69% | 19.98% | 23.25% | 23.23% | 14.75% | 10.95% | 1.08% | 26.58% | 43.24% | 33.88% | 37.63% |
| Other Income | 0.32 | 0.42 | 0.40 | 0.20 | 0.31 | 0.14 | 0.13 | 0.42 | 0.98 | 0.18 | 0.52 | 0.11 |
| Interest | 0.35 | 0.44 | -0.32 | 0.25 | 0.28 | 0.25 | 0.30 | 0.28 | 0.96 | 1.52 | 1.49 | 1.37 |
| Depreciation | 0.27 | 0.27 | 0.28 | 0.27 | 0.27 | 0.27 | 0.29 | 0.27 | 0.65 | 0.98 | 0.90 | 0.91 |
| Profit before tax | 2.73 | 3.79 | 2.85 | 1.01 | 0.48 | 0.07 | 0.35 | -0.10 | 1.72 | 1.74 | 1.46 | 1.13 |
| Tax % | 27.84% | 27.70% | 18.60% | 24.75% | 25.00% | 28.57% | -11.43% | 0.00% | 58.14% | -12.07% | 32.88% | 7.08% |
| Net Profit | 1.97 | 2.73 | 2.32 | 0.75 | 0.36 | 0.05 | 0.39 | -0.11 | 0.72 | 1.95 | 0.97 | 1.05 |
| EPS in Rs | 3.16 | 4.38 | 3.72 | 1.20 | 0.58 | 0.08 | 0.63 | -0.18 | 1.16 | 3.13 | 1.56 | 1.68 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 27.91 | 35.47 | 40.79 | 46.82 | 43.79 | 54.25 | 50.87 | 52.89 | 53.64 | 19.12 | 30.74 | 36.83 |
| Expenses | 25.11 | 31.03 | 34.43 | 39.83 | 37.51 | 43.01 | 46.24 | 48.50 | 42.96 | 15.99 | 20.53 | 23.79 |
| Operating Profit | 2.80 | 4.44 | 6.36 | 6.99 | 6.28 | 11.24 | 4.63 | 4.39 | 10.68 | 3.13 | 10.21 | 13.04 |
| OPM % | 10.03% | 12.52% | 15.59% | 14.93% | 14.34% | 20.72% | 9.10% | 8.30% | 19.91% | 16.37% | 33.21% | 35.41% |
| Other Income | 0.42 | 0.53 | 0.51 | 0.96 | 0.97 | 0.76 | 1.09 | 0.94 | 1.50 | 0.93 | 1.66 | 1.79 |
| Interest | 1.66 | 1.18 | 1.21 | 0.87 | 0.58 | 0.46 | 0.83 | 0.81 | 0.74 | 1.08 | 4.25 | 5.34 |
| Depreciation | 0.68 | 0.86 | 0.93 | 1.01 | 1.02 | 1.04 | 1.02 | 1.07 | 1.09 | 1.10 | 2.81 | 3.44 |
| Profit before tax | 0.88 | 2.93 | 4.73 | 6.07 | 5.65 | 10.50 | 3.87 | 3.45 | 10.35 | 1.88 | 4.81 | 6.05 |
| Tax % | 0.00% | 72.01% | 25.16% | 27.51% | 27.96% | 31.62% | 26.61% | 28.99% | 24.64% | 2.13% | 26.61% | |
| Net Profit | 0.88 | 0.82 | 3.53 | 4.40 | 4.05 | 7.18 | 2.84 | 2.44 | 7.79 | 1.84 | 3.53 | 4.69 |
| EPS in Rs | 1.41 | 1.32 | 5.66 | 7.06 | 6.50 | 11.52 | 4.56 | 3.91 | 12.50 | 2.95 | 5.66 | 7.53 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | 1% | -11% | -17% | 126% | ||
| Compounded Profit Growth | 16% | -12% | 16% | 594% | ||
| Stock Price CAGR | 19% | 15% | 28% | 3% | ||
| Return on Equity | 14% | 10% | 11% | 8% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6.23 | 6.23 | 6.23 | 6.23 | 6.23 | 6.23 | 6.23 | 6.23 | 6.23 | 6.23 | 6.23 | 6.23 |
| Reserves | 1.47 | 2.35 | 3.18 | 6.75 | 11.18 | 15.27 | 22.35 | 25.29 | 27.97 | 35.73 | 36.74 | 40.12 |
| Borrowings | 16.41 | 12.62 | 4.95 | 9.20 | 8.09 | 3.16 | 3.16 | 13.78 | 6.41 | 26.25 | 45.01 | 63.31 |
| Other Liabilities | 4.67 | 4.49 | 12.45 | 8.23 | 7.97 | 7.68 | 10.15 | 9.66 | 15.38 | 17.52 | 11.11 | 11.42 |
| Total Liabilities | 28.78 | 25.69 | 26.81 | 30.41 | 33.47 | 32.34 | 41.89 | 54.96 | 55.99 | 85.73 | 99.09 | 121.08 |
| Fixed Assets | 9.80 | 9.13 | 13.00 | 13.02 | 14.59 | 14.24 | 13.56 | 13.61 | 12.62 | 22.15 | 21.06 | 75.18 |
| CWIP | 0.82 | 3.33 | 0.23 | 1.07 | 0.12 | 0.12 | 0.13 | 3.68 | 7.67 | 32.68 | 56.48 | 14.48 |
| Investments | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.01 |
| Other Assets | 18.11 | 13.18 | 13.53 | 16.27 | 18.71 | 17.93 | 28.15 | 37.62 | 35.65 | 30.85 | 21.50 | 31.41 |
| Total Assets | 28.78 | 25.69 | 26.81 | 30.41 | 33.47 | 32.34 | 41.89 | 54.96 | 55.99 | 85.73 | 99.09 | 121.08 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | -0.78 | 7.88 | 6.49 | 6.05 | 6.87 | 9.30 | 12.82 | -6.59 | 3.28 | 18.81 | 5.02 | 2.11 |
| Cash from Investing Activity | -0.73 | -2.44 | -2.20 | -3.04 | -3.19 | -2.21 | -3.51 | -5.34 | -5.08 | -38.67 | -23.70 | -14.78 |
| Cash from Financing Activity | 0.53 | -5.34 | -3.81 | -1.77 | -1.83 | -5.52 | -0.46 | 9.79 | -8.18 | 19.09 | 17.69 | 14.04 |
| Net Cash Flow | -0.98 | 0.09 | 0.47 | 1.24 | 1.86 | 1.58 | 8.85 | -2.14 | -9.98 | -0.77 | -0.99 | 1.37 |
| Free Cash Flow | -1.55 | 5.36 | 4.86 | 4.25 | 5.25 | 8.63 | 12.44 | -11.20 | -0.79 | 18.81 | -18.78 | -55.03 |
| CFO/OP | -27% | 281% | 146% | 95% | 98% | 148% | 114% | -142% | 75% | 176% | 184% | 21% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 94.80 | 66.04 | 79.13 | 74.90 | 66.26 | 48.18 | 49.12 | 97.65 | 85.57 | 91.11 | 179.25 | 108.65 |
| Inventory Days | 89.37 | 86.72 | 21.65 | 22.00 | 42.98 | 60.54 | 32.60 | 47.32 | 120.27 | 113.24 | 145.45 | 815.53 |
| Days Payable | 56.12 | 72.03 | 80.26 | 78.26 | 66.19 | 70.67 | 73.51 | 54.12 | 117.41 | 85.34 | 246.11 | 281.88 |
| Cash Conversion Cycle | 128.05 | 80.73 | 20.52 | 18.64 | 43.05 | 38.04 | 8.20 | 90.86 | 88.44 | 119.01 | 78.59 | 642.29 |
| Working Capital Days | 39.13 | 26.68 | 67.20 | 64.70 | 63.46 | 51.09 | 29.40 | 36.59 | 104.28 | 35.86 | -26.73 | 6.41 |
| ROCE % | 10.74% | 11.21% | 23.06% | 32.51% | 29.11% | 24.84% | 38.87% | 12.20% | 9.92% | 20.38% | 3.79% | 9.52% |
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 52.09% | 52.09% | 52.15% | 52.15% | 52.15% | 52.15% | 52.17% | 52.17% | 52.17% | 52.17% | 52.17% | 52.40% |
| DIIs | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Public | 47.92% | 47.90% | 47.85% | 47.84% | 47.84% | 47.84% | 47.82% | 47.82% | 47.82% | 47.80% | 47.82% | 47.58% |
| No. of Shareholders | 10,272 | 9,905 | 9,441 | 9,335 | 9,266 | 9,265 | 9,102 | 8,916 | 8,860 | 8,640 | 8,405 | 8,315 |
Fundamentals
Market Cap₹ 153 Cr.
Current Price₹ 245
Stock P/E31.9
Book Value₹ 74.4
ROCE9.52 %
ROE8.49 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)126%
Compounded Profit Growth (TTM)594%
Standalone figures.
Valuation
Market capRs 152 Cr
Enterprise valueRs 214 Cr
P/E (TTM)32.40x
Price to book3.28x
Price to sales4.13x
EV / EBITDA14.40x
EV / EBIT18.75x
EV / sales5.80x
Price to cash flow72.01x
Earnings yield3.09%
P/E, 3-year average45.92x
P/B, 3-year average3.10x
P/E, 5-year average34.75x
P/B, 5-year average2.46x
Profitability
Operating margin (excl. other income)33.21%
Operating margin (incl. other income)38.61%
EBITDA margin40.27%
Pre-tax margin16.43%
Net profit margin12.73%
Net margin, latest quarter11.97%
ROE7.90%
ROCE9.17%
ROA3.21%
ROE, 3-year average10.90%
ROCE, 3-year average11.11%
ROA, 3-year average5.40%
ROE, 5-year average9.91%
ROCE, 5-year average11.09%
ROA, 5-year average5.29%
ROIC (approx.)7.74%
Tax rate26.61%
Other income / net worth3.58%
Growth
Sales growth (latest year)60.77%
Profit growth (latest year)91.85%
Sales CAGR, 3 years-16.55%
Sales CAGR, 5 years-10.74%
Profit CAGR, 3 years13.10%
Profit CAGR, 5 years-13.24%
Sales growth QoQ-10.78%
Profit growth QoQ8.25%
Sales growth YoY (latest quarter)216.61%
Per share
EPS (TTM)Rs 7.53
EPS (latest year)Rs 5.66
EPS (latest quarter)Rs 1.68
EPS, 3-year averageRs 7.04
EPS, 5-year averageRs 5.92
Book value per shareRs 74.37
Sales per shareRs 59.09
Cash flow per shareRs 3.39
Free cash flow per shareRs -88.30
Efficiency
Asset turnover0.25x
Fixed asset turnover0.41x
Inventory turnover0.62x
Inventory days593 days
Debtor days109 days
Debtors turnover3.36x
Creditor days282 days
Cash conversion cycle642 days
Working capital days6 days
Leverage
Total debtRs 63 Cr
Cash and bankRs 2 Cr
Net debtRs 62 Cr
Debt to equity1.37x
Net debt / EBITDA4.16x
Interest coverage2.13x
Owners' fund to total sources38.28%
Debt to assets52.29%
Cash flow
Cash from Operating Activity (latest year)Rs 2 Cr
Cash from Investing Activity (latest year)Rs -15 Cr
Cash from Financing Activity (latest year)Rs 14 Cr
Net Cash Flow (latest year)Rs 1 Cr
Free cash flow (latest year)Rs -55 Cr
FCFE (approx.: FCF + change in debt)Rs -37 Cr
Cash from ops / profit, 5 years1.23x
Sales to cash flow14.57x
Statement figures
Net sales (TTM)Rs 37 Cr
Net sales (latest year)Rs 31 Cr
Sales (latest quarter)Rs 9 Cr
Operating profit excl. other income (latest year)Rs 10 Cr
Operating profit (latest quarter)Rs 3 Cr
Other income (TTM)Rs 2 Cr
EBITDA (TTM)Rs 15 Cr
PBDT (TTM)Rs 9 Cr
Profit before tax (TTM)Rs 6 Cr
Tax (latest year)Rs 1 Cr
Net profit (TTM)Rs 5 Cr
Net profit (latest year)Rs 4 Cr
Net profit (latest quarter)Rs 1 Cr
Depreciation (TTM)Rs 3 Cr
Depreciation (latest quarter)Rs 1 Cr
Interest (TTM)Rs 5 Cr
Cost of goods sold (latest year)Rs 8 Cr
Total expenditure (latest year)Rs 21 Cr
Total income (latest year)Rs 32 Cr
Share capitalRs 6 Cr
ReservesRs 40 Cr
Shareholders' fundsRs 46 Cr
Total assetsRs 121 Cr
Net blockRs 75 Cr
Capital work in progressRs 14 Cr
InvestmentsRs 0 Cr
ReceivablesRs 9 Cr
InventoryRs 14 Cr
Other liabilitiesRs 11 Cr
Shares outstanding (crore)0.62
Ownership
Promoter holding52.40% (+0.23 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/E 32.4 is at the 65th percentile of its own 9.4-year range
(median 16.4, low 4.0, high 208.3).
P/B 3.28 is at the 66th percentile (median 2.81).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | 530233 | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -0.9% | -2.8% | +1.9 pts |
| 1 month | +5.1% | -6.8% | +11.9 pts |
| 3 months | -3.3% | -7.6% | +4.3 pts |
| 3 years | +107.0% | +14.2% | +92.9 pts |
| 5 years | +101.8% | +27.9% | +73.9 pts |
Red flags
F-score 6 of 8| look | Inventory outrunning sales Inventory grew 269% vs sales +61% in 2026 |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹9 Cr +216.6% vs Jun 2025.
Net profit ₹1 Cr +1054.5%.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Auro Laboratories Ltd?
Auro Laboratories Ltd (530233) has a market capitalisation of Rs 153 Cr. at the 2026-10-01 close.
What is the P/E ratio of Auro Laboratories Ltd?
Auro Laboratories Ltd trades at a P/E of 31.9 on trailing twelve-month profit, at the 2026-10-01 close.
What were Auro Laboratories Ltd's latest quarterly results?
In the Jun 2026 quarter, Auro Laboratories Ltd sales was Rs 9 Cr (+216.6% vs Jun 2025) and net profit was Rs 1 Cr.